Skip to content

Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease

Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease: A Prospective Randomized Double-blind Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03053128
Acronym
CSWT
Enrollment
30
Registered
2017-02-14
Start date
2017-01-20
Completion date
2019-11-20
Last updated
2020-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Ischemia

Keywords

cardiac ischemia

Brief summary

Coronary heart disease (CHD) is a public health care challenge. There are three types of treatment for CHD, medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some end-stage CHD patients lost the chance to get those treatment. Cardiac shock wave therapy (CSWT) is a new developed therapy for these patients, which is used in tens of countries all over the world. Safety, invasiveness, effectiveness is its advantage. Ischemia condition can be improved after CSWT. There are only three cities in China run the program of CSWT, which are Kunming, Beijing and Shanghai. The investigators designed a randomized double-blind study to evaluate the effectiveness and safety of CSWT.

Detailed description

Coronary heart disease (CHD) is a public health care challenge, which lead to 3.5 millions of people died in China every year. There are three types of treatment for CHD, medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some end-stage CHD patients with severe cardiac ischemia lost the chance to get those treatment. Their quality of life is influenced by recurrent angina. Cardiac shock wave therapy (CSWT) is a new developed therapy for these patients, which is used in tens of countries all over the world. German and Japan are the countries earliest used CSWT. Safety, invasiveness, effectiveness is its advantage. Ischemia condition can be improved after CSWT by objective examination. New small vessels generation on ischemia area was found on mice and pig model. There are only three cities in China run the program of CSWT, that are Kunming, Beijing and Shanghai. Beijing hospital has the only CSWT machine in Beijing. The investigators designed a randomized double-blind study to evaluate the effectiveness and safety of CSWT.

Interventions

Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.

OTHERSham cardiac shock wave (Control group)

Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.

Sponsors

Beijing Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Multiple or diffused coronary artery stenosis by coronary angiography and not candidate for PCI or CABG; 2. Myocardial ischemia and/or cardiac dysfunction by objective exams; 3. Angina and/or heart failure could not be control after optimal medication treatment for coronary artery disease; 4. LVEF is above 30%; 5. Signed informed consent

Exclusion criteria

1. Acute myocardial infarction; 2. Within one month after PCI or CABG; 3. Heart transplant patient; 4. Mechanic valve implantation patient; 5. Uncontrolled heart failure with LVEF less than 30%; 6. Severe arrhythmia; 7. Pacemaker implantation patient; 8. Infective endocarditis; 9. Severe chronic obstructive pulmonary disease patient; 10. Pregnant or nursing patient; 11. Silicone breast forms patient; 12. Chest tumor patient; 13. Participant in other clinical trials at the same time.

Design outcomes

Primary

MeasureTime frameDescription
Myocardial perfusion score1st week of fourth month from beginning of CSWTMyocardial perfusion score will be calculated by myocardial perfusion imaging though single-photon computer tomography.
Ischemia area percentage1st week of fourth month from beginning of CSWTIschemia area will be calculated by myocardial perfusion imaging though single-photon computer tomography.

Secondary

MeasureTime frameDescription
Cardiac enzymeFirst week after CSWTTroponin T and troponin I will be tested at last time shock wave therapy of the first week.
Angina score-SAQ1st week of fourth month from beginning of CSWTSAQ angina score will be finished after three month of CSWT.
Cardiac wall motion amplitude1st week of fourth month from beginning of CSWTCardiac wall motion amplitude rate will be calculated by single-photon computer tomography.
Six-minute of walk test1st week of fourth month from beginning of CSWT6MWT will be used for exertional capacity.
Quality of life (SF-36)1st week of fourth month from beginning of CSWTSF-36 questionnaire will be used for QOL.
Left ventricular thickness rate1st week of fourth month from beginning of CSWTLeft ventricular thickness rate will be calculated by single-photon computer tomography.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026